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Anti-CD19 chimeric antigen receptor-modified T (CAR-T-19) cells have emerged as a powerful targeted immunotherapy for 
B-cell lineage acute lymphoblastic leukemia with a remarkable clinical response in recent trials. Nonetheless, few data are 
available on the subsequent clinical monitoring and treatment of the patients, especially those with disease recurrence after 
CAR-T-19 cell infusion. Here, we analyzed three patients who survived after our phase I clinical trial and who were studied by 
means of biomarkers reflecting persistence of CAR-T-19 cells in vivo and predictive factors directing further treatment. One 
patient achieved 9-week sustained complete remission and subsequently received an allogeneic hematopoietic stem cell trans-
plant. Another patient who showed relapse after 20 weeks without detectable leukemia in the cerebrospinal fluid after 
CAR-T-19 cell treatment was able to achieve a morphological remission under the influence of stand-alone low-dose chemo-
therapeutic agents. The third patient gradually developed extensive extramedullary involvement in tissues with scarce im-
mune-cell infiltration during a long period of hematopoietic remission after CAR-T-19 cell therapy. Long-term and discontin-
uous increases in serum cytokines (mainly interleukin 6 and C-reactive protein) were identified in two patients (Nos. 1 and 6) 
even though only a low copy number of CAR molecules could be detected in their peripheral blood. This finding was sugges-
tive of persistent functional activity of CAR-T-19 cells. Combined analyses of laboratory biomarkers with their clinical mani-
festations before and after salvage treatment showed that the persistent immunosurveillance mediated by CAR-T-19 cells 
would inevitably potentiate the leukemia-killing effectiveness of subsequent chemotherapy in patients who showed relapse af-
ter CAR-T-19-induced remission.  
chimeric antigen receptor T cells, B-cell acute lymphoblastic leukemia, biomarker, immunosurveillance, 
microenvironment 
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INTRODUCTION 
Engineering of T lymphocytes to express chimeric antigen 
receptors (CARs) that target antigen CD19 (CAR-T-19 
cells) in patients with B-cell lineage acute lymphoblastic 
leukemia (B-ALL) has attracted much attention because the     
corresponding clinical trials showed promising results: im-
pressive clinical responses in heavily pretreated patients. 
Thus far, seven clinical trials involving 72 ALL patients 
treated with CAR-T-19 cells (targeting CD19) have been 
reported. These treatments induced CR in 60 (83%) of 72 
patients including patients with minimal residual disease 
(MRD+) or CR (Lorentzen and Straten, 2015). Particularly 
notable is the report of Maude where 90% of the patients 
were in morphological complete remission at the first as-
sessment one month after infusion of CAR-T-19 cells 
(Maude, 2014). On the other hand, only statistically signifi-
cant data were provided, and there are few reports about the 
detailed information on these patients after treatment. This 
year, we reported the findings from the first nine adult pa-
tients with relapsed or chemotherapy-refractory B-ALL who 
we enrolled in treatment with autologous or donor-derived 
T cells that were genetically modified to express a CAR 
targeting the B-cell antigen CD19 and harboring the 4-1BB 
and CD3 moieties (Hanren et al., 2015). During the fol-
low-up period, we observed interesting phenomena in three 
of the nine patients. Here, the details of these cases are re-
ported. 
PRESENTATION OF CASES 
Case 1 
Patient No. 1 from the previous report was a 49-year-old 
woman who had a diagnosis of Ph-positive B-ALL and 
never achieved molecular remission. She was BCR/ABL 
(breakpoint cluster region/Abelson leukemia virus) fusion 
gene-negative after multiple cycles of chemotherapy and 
treatment with molecularly targeted drugs; thus, a hemato-
poietic stem cell transplant was not possible. On day 23 
after CAR-T-19 cell infusion, analyses of bone marrow 
(BM) aspiration samples from the iliac crest confirmed 
complete remission and BCR/ABL-negative status. Subse-
quently, sustained molecular remission was observed during 
the follow-up period of nine weeks. Consequently, the pa-
tient later underwent an HLA-matched allogeneic hemato-
poietic stem cell transplant from an unrelated marrow donor 
and has remained disease-free until now. Additionally, this 
patient exhibited intermittent fevers and continuous cough 
for the 133 d after the CAR-T-19 cell infusion. Laboratory 
testing revealed obvious upregulation of C-reactive protein 
(CRP), tumor necrosis factor  (TNF-), and interleukin 6 
(IL-6). Additionally, a computed tomography (CT) scan of 
the lungs revealed a pulmonary infection and terminal 
bronchiectasis in the inferior lung that showed no noticeable 
improvement after multiple anti-infection treatments. These 
clinical signs were assumed to be the result of cytokine re-
lease syndrome (CRS). After a subcutaneous infliximab 
injection, the fever and cough subsided, and accordingly, 
the focus of infection disappeared on CT scans (Figure 1). 
 
 
Figure 1  A, Comparison of computed tomography (CT) scans of the lungs in different periods (before, during, and after cytokine release syndrome 
[CRS]). Red arrows indicate infection-like responses in the lungs. B, Fluctuation of CRS-related biomarkers after infusion of anti-CD19 chimeric antigen 
receptor-modified T (CAR-T-19) cells.  
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Case 2 
Patient No. 6 from the previous report was a 32-year-old 
man with a 3-year history of chronic myelogenous leukemia 
who transitioned to Ph-positive B-ALL status 17 months 
earlier and showed detectable central nervous system (CNS) 
leukemia. This patient failed to achieve remission after mul-
tiple cycles of intensive chemotherapy and was referred to 
us for CAR-T-19 cell therapy. At the time of enrollment, he 
had CNS 3 status (i.e., 5 white blood cells [WBCs] μL1 
and cytospin positivity of blasts or a traumatic spinal tap 
with 10 red blood cells [RBCs]/μL and cytospin positivity 
of blasts) and high cerebrospinal fluid (CSF) pressure (300 
mmH2O). Assessment on day 28 revealed minimal residual 
disease and complete remission with a BCR/ABL level of 
0% in the CSF. The patient showed rapid relapse after the 
early loss of CAR-T-19 cells at 20 weeks. To our surprise, 
however, this patient presented with severe tumor lysis syn-
drome (TLS) and achieved complete remission again only 
after an intrathecal injection of cytarabine (50 mg), metho-
trexate (10 mg), and dexamethasone (5 mg). Additionally, 
on the subsequent days, the patient showed durable  
remission with regular intrathecal injections each month 
(Figure 2). 
Case 3 
Patient No. 7 in the previous report was a 44-year-old man 
who was admitted with Ph-positive B-ALL with CNS leu-
kemia after a relapse following an allogeneic hematopoietic 
stem cell transplant from an HLA-matched identical sibling 
donor. On treatment day 21 after the CAR-T-19 cell infu-
sion, BM and CSF analyses confirmed complete remission 
and BCR/ABL negativity, respectively. The patient exhib-
ited continued remission according to the BM and CSF tests 
until two or three lumps were identified in the subcutaneous 
tissue in the 30th week after CAR-T-19 cell infusion.  
Leukemic cells were found to have generally infiltrated 
the adipose tissue according to a biopsy and immunohisto-
chemical staining (IHC; Figure 3). Nearly simultaneously, 
the patient developed a limp, and a typical diffuse infiltra-
tive lesion with bone destruction was directly observed on 
magnetic resonance imaging (MRI) of the lower limbs and 
lumbar vertebrae. 
BIOMARKERS AND SYMPTOMATOLOGY  
In the past few years, a variety of approaches based on the 
adoptive transfer of cells with specific and enhanced anti-
tumor effects have been developed (Ghorashian et al., 2015; 
Brentjens et al., 2013; Zhu et al., 2015 ). The essential ob-
jectives of immunotherapy as a treatment of cancer are the 
following (Kalos, 2011): (i) to drive potent antitumor im-
munity that leads to remission and (ii) to establish 
long-lasting immunity by targeting antigens and the tumor 
with CAR-T cell therapies that require identification of the 
 
Figure 2  Fluctuation of tumor lysis-related biomarkers after single-agent 
low-dose chemotherapy in the patient who showed relapse after infusion of 
CAR-T-19 cells. Blue dotted lines represent the upper limit of the reference 
range of the serum indexes. The red arrows represent each injection of a 
chemotherapeutic agent. 
relevant and informative biomarker strategies for the sup-
port, guidance, and detection of clinical developments, effi-
cacy, clinical responses (or results), adverse effects, and the 
potential of such approaches to stimulate antitumor activity 
throughout research and development (Lacey et al., 2013). 
Additionally, the primary objectives of the clinical trials of 
CAR-T cells are to evaluate the safety and clinical efficacy 
of the novel therapeutic agents (Lacey et al., 2013). There- 
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Figure 3  Biopsy samples showing extramedullary involvement in the 
subcutaneous adipose tissue of the chest wall and immunohistochemical 
staining (IHC) for CD19 and CD3; leukemic cells escape to the affected 
extramedullary tissue that CAR-T-19 cells could not infiltrate. 
fore, we needed to define standard relevant biomarkers by 
first establishing principles for the development and use of 
biomarkers in clinical research and then by devising a ra-
tionale and a strategy for the integration of biomarker data 
across all stages of the product development process from 
preclinical studies through product manufacturing (and 
during the clinical trial). Finally, the different classes of 
biomarkers that are relevant to T-cell therapy trials have to 
be identified (Lacey et al., 2013). Accordingly, a CAR-T-19 
cell clone was engineered for adoptive therapeutic use 
against cancer, and there is increasing interest in identifica-
tion of sensitive, robust, and meaningful biomarkers that 
may provide relevant insights into the clinical development 
process (Fox et al., 2011; Butterfield et al., 2011).  
Cytokine release syndrome (CRS)-related biomarkers 
The risks associated with CAR-T cell immunotherapy can 
be broadly classified into autoimmune adverse effects and 
cytokine-associated toxicity (Lee et al.. 2014). Cytokine-  
associated toxicity, also known as CRS, is a non-      
antigen-specific toxicity that occurs as a result of high-level 
immune activation (Lee et al., 2014). CAR-T cells can in-
duce a clinical syndrome involving fever, hypotension, hy-
poxia, and neurological changes that are associated with 
marked upregulation of serum cytokines in some patients 
(Brentjens et al., 2013; Grupp et al., 2013; Kochenderfer et 
al., 2012). Because CRS occurs as a direct result of su-
praphysiological levels of proinflammatory cytokines, cir-
culating cytokine levels could serve as biomarkers for the 
diagnosis of this syndrome and for measurement of the syn-
drome severity (Lee et al., 2014). CRS is associated with 
elevated circulating levels of several cytokines, including 
CRP, IL-6, IL-10, and interferon  (IFN) (Lee et al., 2014). 
CRP 
This protein is an acute phase reactant produced by the liver 
largely in response to IL-6, and CRP levels serve as a relia-
ble surrogate for IL-6 bioactivity (Schultz et al., 1990; 
Pepys et al., 2003). In some studies, peak CRP levels and 
fold changes in CRP have been used to identify patients 
who are at risk of severe CRS (Davila et al., 2014). There-
fore, routine monitoring of CRP levels when CRS symp-
toms are present may have clinical utility (Lee et al., 2014). 
Nevertheless, it is important to emphasize that CRP levels 
are also elevated during an infection and cannot be used to 
distinguish infection-associated inflammation from nonin-
fectious inflammation (Arkader et al., 2006). 
IL-6 
This protein is a pleiotropic cytokine with anti-inflamma- 
tory and proinflammatory properties and is involved in a 
large number of processes within the immune system (Lee 
et al., 2014; Maude et al., 2014). In patients with severe 
CRS associated with CAR-T cell-engaging therapies, IL-6 
levels peak during maximal T-cell proliferation. Research-
ers theorized that targeting IL-6 might reduce CRS severity 
without compromising the clinical efficacy of CAR-T 
cell-engaging therapies (Maude et al., 2014). 
IL-10 
This cytokine is produced by mast cells, B cells, regulatory 
T cells, and helper T cells but is not commonly produced by 
cytotoxic T lymphocytes. As a negative regulator, IL-10 
may not be an ideal therapeutic target in CRS (Maude et al., 
2014).  
IFN- 
This IFN is also a proinflammatory cytokine and is pro-
duced by cytotoxic T cells, helper T cells (TH1), and natural 
killer cells (Saha et al., 2010). As an effector cytokine that 
is released by activated cytotoxic T cells after cellular en-
gagement, IFN- is expected to be upregulated and is likely 
required for efficacy; therefore, IFN- is a potentially unde-
sirable target for management of adverse effects (Maude et 
al., 2014).  
TLS 
This is a collection of metabolic aberrations that leads to a 
release of intracellular contents after the lysis of malignant 
cells and is characterized by hyperuricemia, hyperkalemia, 
hyperphosphatemia, and hypocalcemia that result from 
massive cell death and the release of intracellular uric acid, 
potassium, and phosphate (Will et al., 2011; Howard et al., 
2011; Rasool et al., 2014). The released intracellular metab-
olites include nucleic acids, proteins, phosphorus, and po-
tassium and lead to hyperuricemia, hyperkalemia, hyper-
phosphatemia, hypocalcaemia, and uricemia (Cairo et al., 
2004). Electrolyte and metabolic disturbances can lead to 
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renal insufficiency, cardiac arrhythmias, seizures, and even 
death due to multiple organ failure (Howard et al., 2011). 
The majority of TLS cases occur after treatment of a hema-
tological cancer, such as ALL and Burkitt’s lymphoma, 
followed by chemotherapy, radiotherapy, hormonal therapy, 
or immunotherapy (Rasool et al., 2014). The risk factors of 
TLS include a large tumor burden, high proliferation rates, 
and disease that is highly responsive to therapy. Studies 
have indicated the usefulness of blood creatinine, uric acid, 
lactate dehydrogenase, albumin, sodium, potassium, calci-
um, and phosphor in the diagnosis, prognosis, and man-
agement of TLS (Howard et al., 2011). 
B-cell aplasia 
Induction of B-cell aplasia is expected and indicative of 
functional CAR T cells in patients with relapsed acute leu-
kemia (Grupp et al., 2013). Persistent B-cell aplasia sug-
gests that the CAR-T-19 cells are exerting substantial and 
sustained effector functions in advanced ALL (Grupp et al., 
2013). With the exception of B-cell aplasia, the duration of 
which is currently undefined, immune-system-based thera-
pies such as CAR-T-19 may have favorable long-term pro-
files of adverse effects as compared to the high-dose regi-
mens of chemotherapy and radiation therapy, which are the 
current standard of care for most cases of relapsed leukemia 
(Garcia-Manero et al., 2001). 
RESULTS 
Persistent remission in Patient No. 1  
The clinical remission in Patient No. 1 was associated with 
molecular remission that persisted for more than nine 
weeks. Overall, this patient maintained persistent remission 
after the subcutaneous infliximab injections for the CRS in 
both lungs without any influence on the function of the 
CAR-T-19 cells in her body. 
TLS after intrathecal injection in Patient No. 6 
This patient showed relapse after the early loss of the 
CAR-T-19 cells at 20 weeks. Nevertheless, a rare response 
was observed after the intrathecal injection of cytarabine 
(50 mg), methotrexate (10 mg), and dexamethasone (5 mg). 
This patient developed severe TLS but again achieved com-
plete remission. Additionally, in the subsequent days, he 
maintained durable remission with regular intrathecal injec-
tions each month. Moreover, he showed varying degrees of 
TLS at the time of each intrathecal injection, including the 
most serious complications of TLS, such as renal failure, 
ventricular fibrillation, and cardiac arrest. Fortunately, the 
patient was successfully rescued and he is currently alive 
and cancer free.  
Immune escape in Patient No. 7 
With the continuous remission in the BM and CSF, this 
patient developed transferred extramedullary leukemia in 
the subcutaneous fatty tissue and skeletal system in the 30th 
week after CAR-T-19 cell infusion with continuous B-cell 
aplasia. 
DISCUSSION  
Relevant biomarker data can be obtained from evaluation of 
patients before, during, and after treatment. In particular, 
factors such as a patient’s immune status, the tumor pheno-
type, and the local immune environment may influence the 
effectiveness of therapeutic modalities. In the present study, 
we sought to discuss how biomarkers can play a central role 
in the use of CAR-T cell therapeutic agents and to highlight 
how appropriately designed biomarker studies can provide 
critical insights into this process. Here, we discuss future 
directions and challenges for the appropriate use of bi-
omarkers for evaluating product bioactivity and treatment 
efficacy. 
Adverse pulmonary events caused by the immunological 
responses mediated by CAR-T-19 cells 
Pulmonary events occur frequently and to varying degrees 
in patients who have received CAR-T cell infusions ac-
cording to clinical observations. Such events are an im-
portant indicator for the development of standards for clini-
cal trials and for identifying the differences between an in-
fection and adverse events in the lungs. Additionally, we 
found that patients who develop pulmonary infiltrates ex-
hibit more severe adverse events than do patients without 
pulmonary infiltrates. Wang et al. researched CD20-directed 
chimeric antigen receptor-modified T cells in a patient with 
primary extranodal lymphoma involving the right intrap-
ulmonary tissue (Wang et al., 2014). This patient gradually 
developed dyspnea and respiratory distress, which were 
temporarily alleviated by intravenous administration of 
glucocorticoids. The patient’s respiratory distress ultimately 
progressed until it required bed rest and the use of an oxy-
gen mask. Consequently, extramedullary B-cell tumors in 
the lungs are listed as a contraindication for CAR-T therapy.  
Immunological tumor microenvironment (TME) and 
immune escape 
The term TME is used to describe certain parts of the body 
in which surrounding cells and tissues can affect the growth 
of specific cells by altering pH, oxygen levels, and other 
factors (Bakker et al., 2015). The effects of the TME on 
hematological cancers are particularly interesting and typi-
cally involve several levels of crosstalk between leukemic 
cells and the bone marrow microenvironment (Bakker et al., 
2015). Tumors are well adapted to overcome productive 
immune responses via multiple mechanisms that prevent 
effective killing of T cells and the maintenance of function-
al activity (Ghorashian et al., 2015). Furthermore, 
CAR-T-19 cells are prone to target the bone marrow rather 
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than extramedullary leukemia with higher density and 
hypovascular regions (Yang et al., 2012; Burger et al., 
2014; Christopoulos et al., 2011). Hence, the “smart leuke-
mic cells” migrate to locations that are difficult for the 
CAR-T-19 cells to reach. For example, the fatty layer and 
the skeletal system are relatively ideal shelters for leukemic 
cells to escape the immunity-mediated cytocidal antitumor 
effect. This process may be a probable interpretation or hy-
pothesis about the observations in patient No. 7 who 
showed extramedullary leukemia in the fatty layer and skel-
etal system without a BM and CSF relapse (Hanren et al., 
2015). Eventually, future developments in CAR design need 
to overcome the antigenic escape and inhibition by the TME 
(Ghorashian et al., 2015). 
Immune tolerance and immunosurveillance 
The immune response is responsible for the control of nas-
cent cancer through immunosurveillance (Schreiber et al., 
2011). Eventually, the inherent genetic instability of tumor 
cells leads to the development of immunity evasion mecha-
nisms, e.g., the loss of tumor-associated antigens (TAAs), 
downregulation of MHC antigen expression, T-cell inacti-
vation due to reduced T cell receptor (TCR) signaling, and 
IL-10- and transforming growth factor (TGF)--mediated 
suppression (Schreiber et al., 2011). These mechanisms 
induce a state of immune tolerance and inactivate tu-
mor-specific T cells; this situation renders the immune sys-
tem incapable of recognizing TAAs and of mounting an 
effective immune response against them. This low immu-
nogenicity and subsequent induction of immune tolerance 
remain the most difficult obstacles for effective cancer im-
munotherapy (Marr et al., 2012). According to the seminal 
theory of immune tolerance and immunosurveillance, we 
hypothesized that TAAs could be recognized by CAR-T-19 
cells in the early period after infusion and that greater effi-
cacy in the induction of remission could be achieved in the 
clinical response. Subsequently, the inherent genetic insta-
bility of leukemia leads to the loss of TAAs and develop-
ment of immune evasion independent of the downregulation 
of MHC antigen expression. Once the TAAs are again pre-
sent via intrathecal chemotherapeutic injections, they can 
immediately be recognized by the CAR-T-19 cells due to 
on-target toxicity, which stimulates a cytokine storm and 
subsequent organ failure. This scenario is probably the best 
explanation for the observation that patient No. 6 repeatedly 
achieved complete remission after the intrathecal injections 
despite the relapse of the underlying B-cell aplasia. This 
scenario also means that the CAR-T-19 cells still have pos-
sible powerful actions within the framework of the existing 
biological responsiveness. 
In summary, we presented some concrete examples of 
CAR-T-19 cell therapy and their individual phenomena 
from our phase I clinical trial. Further research is needed to 
maximize the efficacy and to limit the adverse effects. The 
optimal CAR design and optimal effector T-cell populations 
need to be determined as does the durability of the clinical 
response. Moreover, personalized treatments, i.e., precise 
cancer therapy, should be the direction of future medical 
developments. The studies of individual differences in var-
ious treatment responses to achieve good resolution are ex-
pected to become the primary goal of CAR-T therapy in the 
future. This process will also direct and motivate us to iden-
tify imperfections and improve the process of research and 
development within our group.  
METHODS 
We analyzed three of the nine patients on whom our first 
report was based regarding relapsed or chemothera-
py-refractory B-ALL after the administration of autologous 
or donor-derived T cells that were genetically modified to 
express a CAR that targets the B-cell antigen CD19 and 
harbored the 4-1BB and the CD3 moieties. The protocol 
(ClinicalTrials.gov identifier NCT01864889) was approved 
by the Institutional Review Board of the Chinese PLA Gen-
eral Hospital. All authors discussed and interpreted the re-
sults and vouch for the data and analyses. No commercial 
sponsors were involved in the study. The materials and 
methods were reported previously (Hanren et al., 2015).  
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